Expertise & Experience

Key Milestones

Programme Statistics and Outcomes

Today, the programme serves patients from Singapore and across the region, providing access to advanced transplant and cellular therapy treatments supported by internationally benchmarked standards of care.

Source: Data derived from the KKH Paediatric Blood and Marrow Transplant and Cellular Therapy Programme’s internal transplant outcomes database. Analysis based on patients transplanted between 2016 and 2025.

Quality & Accreditation

In 2026, the KKH Paediatric Blood and Marrow Transplant and Cellular Therapy (BMTCT) Programme achieved FACT accreditation, demonstrating compliance with internationally recognised standards in blood and marrow transplantation and cellular therapy.

KKH is the first stand-alone paediatric blood and marrow transplant and cellular therapy programme in Asia to attain this accreditation, reflecting our commitment to quality, safety and continuous improvement in patient care.

Our programme is further supported by a GMP-compliant cellular processing laboratory, ensuring that cellular therapy products are processed and handled in accordance with rigorous quality standards.

Advancing Paediatric Transplantation and Cellular Therapy

Our commitment to advancing paediatric transplantation and cellular therapy is reflected in several recent developments.

In 2022, KKH launched the Children's Blood and Cancer Centre (CBCC) to strengthen paediatric blood and cancer care, research and innovation. The BMTCT Programme serves as one of the Centre's research cores, contributing expertise in blood and marrow transplantation, cellular therapy and translational research.

In the same year, the Teo Sok Yong and Goh Cheng Liang Childhood Cancer Laboratory@KKH was established as a GMP-compliant facility to support advanced cellular processing, translational research and the development of novel cellular therapies.

The programme also collaborates closely with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) to advance cellular therapy research and innovation for both adult and paediatric populations.

In 2023, the programme began offering commercial CAR-T cell therapy in partnership with Novartis, providing eligible patients with access to this advanced treatment in Singapore.

Our Transplant Programmes